Overture Life Appoints Former Butterfly Network Executive Matt Combs as Chief Commercial Officer to Lead Scale-up of IVF Automation Technology as Demand Surges Worldwide
Combs has over 15 years of experience driving rapid revenue growth and scaling organizations across healthcare and medtech, from startups to Fortune 500 companies. He most recently served as Chief Growth Officer at Amalgam, where he led the market expansion of the company's SaaS products. In 2017, Combs joined Butterfly Network as the first commercial hire when the company was pre-revenue, helping scale operations to over $70 million in annual revenue before the company went public in 2021. During his tenure, he transitioned from leading early-stage business development to serving as VP of Sales for the business, managing the commercial organization through periods of rapid growth. He has also held commercial leadership roles at Boston Scientific, Stryker, and FUJIFILM Sonosite.
'We're seeing clinics from the US and Europe, to Latin America and Asia asking when they can get our systems,' said Hans Gangeskar, CEO of Overture Life. 'Matt's track record building Butterfly Network into a public company gives us exactly the commercial expertise we need as we move from proving our technology works to scaling it globally. The demand is increasing exponentially as clinics want automation that actually delivers tangible results.'
'What I've seen with Overture's technology reminds me of the early excitement around Butterfly Network, that sense of a solution arriving at exactly the right moment,' said Combs. 'IVF has been constrained by manual processes that create barriers to accessibility and inconsistency in performance. Overture's automation addresses real operational challenges that clinics face every day, from embryologist shortages to the need for affordable and predictable outcomes.'
About Overture Life
Overture Life integrates engineering, reproductive medicine, and regulatory-grade validation to modernize embryology lab procedures, particularly fertility preservation and embryo handling, in ways that lower repeated cycles, increase throughput, and reduce the overall cost of IVF. With R&D in Spain and active U.S. operations, including a CLIA-licensed laboratory for non-invasive embryo selection, Overture unites robotics, analytics, and clinical rigor to deliver tools that clinics and patients can trust. The company's DaVitri platform aims to boost reliability and consistency in IVF, giving women and families worldwide more control over their fertility timelines. Overture's backers include Overwater Ventures, GV (formerly Google Ventures), Khosla Ventures, Octopus Ventures and others committed to advancing the future of fertility.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 days ago
- Yahoo
Butterfly Network to Report Second Quarter 2025 Financial Results on August 1, 2025
BURLINGTON, Mass. & NEW YORK, July 18, 2025--(BUSINESS WIRE)--Butterfly Network, Inc. (NYSE: BFLY) ("Butterfly"), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, announced that it will report second quarter 2025 financial results on August 1, 2025 before the market opens. Joseph DeVivo, President, Chief Executive Officer and Chairman of the Board, and Heather Getz, Executive Vice President and Chief Financial and Operations Officer, will host a conference call and webcast at 8:00 am ET on August 1 to discuss the financial performance and operational progress. The conference call will be broadcast live in listen-only mode via a webcast on Butterfly's Investor Relations website at Events & Presentations. Individuals interested in listening to the conference call on your telephone may do so by dialing approximately ten minutes prior to start time: United States (Toll-Free): +1 833-470-1428United States (Local): +1 404-975-4839Global Dial-In Numbers: Access Code: 685760 After the live webcast, the call will be archived on Butterfly's Investor Relations page. In addition, a telephone replay of the call will be available until August 15, 2025, by dialing: United States (Toll-Free): +1 866 813 9403United States (Local): +1 929 458 6194Access Code: 128350 About Butterfly Network Butterfly Network, Inc. (NYSE: BFLY) is a healthcare company driving a digital revolution in medical imaging with its proprietary Ultrasound-on-Chip™ semiconductor technology and ultrasound software solutions. In 2018, Butterfly launched the world's first handheld, single-probe, whole-body ultrasound system, Butterfly iQ. The iQ+ followed in 2020, and the iQ3 in 2024, each with improved processing power and performance by leveraging Moore's Law. The iQ3 earned Best Medical Technology at the 2024 Prix Galien USA Awards, a prestigious honor and one of the highest accolades in healthcare. Butterfly's innovations have also been recognized by Fierce 50, TIME's Best Inventions and Fast Company's World Changing Ideas, among other achievements. Butterfly combines advanced hardware, intelligent software, AI, services, and education to drive adoption of affordable, accessible imaging. Clinical publications demonstrate that its handheld ultrasound probes paired with Compass™ enterprise workflow software, can help hospital systems improve care workflows, reduce costs, and enhance provider economics. With a cloud-based solution that enables care anywhere through next-generation mobility, Butterfly aims to democratize healthcare by addressing critical global healthcare challenges. Butterfly devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, Australia, Europe, the Middle East, North America and South America; to learn more about available countries, visit: View source version on Contacts Butterfly Investors: Heather GetzChief Financial and Operations Officer, Butterflyinvestors@ Sign in to access your portfolio
Yahoo
17-07-2025
- Yahoo
Overture Life Signs Agreement With Memorial Hospital Istanbul for World's First Commercial Automated IVF Technology
Overture's ICSI.A technology enabled first babies born from automated fertilization in 2023 Platform will now support one of the highest volume IVF clinics in the world at Memorial Hospital Istanbul, expected to assist in over 6,000 IVF cycles per year – and growing PALO ALTO, Calif., July 17, 2025--(BUSINESS WIRE)--Overture Life, the innovator modernizing IVF to optimize reproductive freedom, announced the first commercial sale of an automated in vitro fertilization (IVF) platform to Memorial Hospital Istanbul, home to one of Europe's leading fertility centers. Overture's ICSI.A platform automates a complex fertilization process known as piezo-assisted intracytoplasmic sperm injection (piezo-ICSI), which uses electric pulses to fertilize eggs more gently than manual injection methods. Overture's ICSI.A enabled the first live births resulting from an automated fertilization1, in 2023. Memorial Hospital Istanbul will use the devices to simplify thousands of IVF cycles per year, with the additional efficiency expected to grow its capacity even further. The growth of automated IVF technologies is critical for patients dealing with infertility, who often struggle to access IVF, whether due to cost, capacity or the toll that multiple IVF cycles can take, emotionally and physically. Overture is dedicated to making IVF easier to perform and less expensive, enabling every embryologist and IVF center to provide premium quality regardless of location, size, or clientele. The company is now poised for rapid commercial growth, backed by peer-reviewed science and rigorous regulatory oversight. Published data suggests piezo-ICSI leads to better quality eggs and blastocytes2, resulting in higher fertility rates. In particular, ICSI.A has demonstrated high proficiency even when operated by inexperienced personnel3 – an important factor given the years of training and practice typically needed to optimize this skillset among embryologists. "Memorial Hospitals have some of the best embryologists in the world, making us a magnet in the region for those struggling with infertility. Despite our proficiency, demand continues to rise, and we are committed to maintaining the best quality as we expand capacity," said Prof Dr Semra Kahraman of the In Vitro Fertilization (IVF) Andrology and Genetics Center at Memorial Hospital Istanbul. "Automated platforms like Overture Life's ICSI.A are game-changing technologies, and will be key for helping us scale effectively." "This exciting commercial commitment from Memorial Hospital, known worldwide for its impressive IVF clinic, is the latest milestone to cement Overture's leadership in the IVF automation space," said Hans Gangeskar, CEO of Overture Life. "This year has already seen a sizable strategic fundraise, regulatory clearance and commercialization for our DaVitri platform for fertility preservation, and CLIA licensure for our AI-powered, non-invasive metabolomic test for embryo selection, m|z. We look forward to rolling out ICSI.A in Turkey and changing the lives of more families eager to take control of their own destiny." Memorial Hospital Istanbul is expected to install Overture Life's ICSI.A robots by the end of this year. About Overture Life Overture Life integrates engineering, reproductive medicine, and regulatory-grade validation to modernize embryology lab procedures, particularly fertility preservation and embryo handling, in ways that lower repeated cycles, increase throughput, and reduce the overall cost of IVF. With R&D in Spain and active U.S. operations, including a CLIA-licensed laboratory for non-invasive embryo selection, Overture unites robotics, analytics, and clinical rigor to deliver tools that clinics and patients can trust. The company's DaVitri platform aims to boost reliability and consistency in IVF, giving women and families worldwide more control over their fertility timelines. Overture's backers include Overwater Ventures, GV (formerly Google Ventures), Khosla Ventures, Octopus Ventures and others committed to advancing the future of fertility. 1 The first babies conceived with a sperm-injecting robot have been born [Internet]. MIT Technology Review. Available from: 2 Furuhashi K, Saeki Y, Enatsu N, Iwasaki T, Ito K, Mizusawa Y, Matsumoto Y, Kokeguchi S, Shiotani M. Piezo-assisted ICSI improves fertilization and blastocyst development rates compared with conventional ICSI in women aged more than 35 years. Reprod Med Biol. 2019 Aug 24;18(4):357-361. doi: 10.1002/rmb2.12290. PMID: 31607795; PMCID: PMC6780025.3 Costa-Borges N, Munné S, Albó E, Mas S, Castelló C, Giralt G, Lu Z, Chau C, Acacio M, Mestres E, Matia Q, Marquès L, Rius M, Márquez C, Vanrell I, Pujol A, Mataró D, Seth-Smith M, Mollinedo L, Calderón G, Zhang J. First babies conceived with Automated Intracytoplasmic Sperm Injection. Reprod Biomed Online. 2023 Sep;47(3):103237. doi: 10.1016/ Epub 2023 May 25. PMID: 37400320. View source version on Contacts Media Contact overture@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
15-07-2025
- Business Wire
Overture Life Appoints Former Butterfly Network Executive Matt Combs as Chief Commercial Officer to Lead Scale-up of IVF Automation Technology as Demand Surges Worldwide
PALO ALTO, Calif.--(BUSINESS WIRE)--Overture Life, the leader in automated IVF technology that delivered the first live births in the world from automated fertilization and egg freezing, today announced the appointment of Matthew Combs as Chief Commercial Officer (CCO). Combs joins Overture to drive global expansion amid rising domestic and international demand for IVF automation technology that directly addresses the embryologist shortages worldwide. In the newly created role, Combs will lead the company's global commercialization as it expands access to technology that automates fertilization and egg freezing processes previously done by hand. These include the ICSI.A, the world's first robot for automated fertilization, and the DaVitri, for automated, consistent, high-quality vitrification that will expand egg freezing beyond specialized IVF facilities. Combs will focus on scaling Overture Life's fertility technologies to meet growing clinic demand. Combs has over 15 years of experience driving rapid revenue growth and scaling organizations across healthcare and medtech, from startups to Fortune 500 companies. He most recently served as Chief Growth Officer at Amalgam, where he led the market expansion of the company's SaaS products. In 2017, Combs joined Butterfly Network as the first commercial hire when the company was pre-revenue, helping scale operations to over $70 million in annual revenue before the company went public in 2021. During his tenure, he transitioned from leading early-stage business development to serving as VP of Sales for the business, managing the commercial organization through periods of rapid growth. He has also held commercial leadership roles at Boston Scientific, Stryker, and FUJIFILM Sonosite. 'We're seeing clinics from the US and Europe, to Latin America and Asia asking when they can get our systems,' said Hans Gangeskar, CEO of Overture Life. 'Matt's track record building Butterfly Network into a public company gives us exactly the commercial expertise we need as we move from proving our technology works to scaling it globally. The demand is increasing exponentially as clinics want automation that actually delivers tangible results.' 'What I've seen with Overture's technology reminds me of the early excitement around Butterfly Network, that sense of a solution arriving at exactly the right moment,' said Combs. 'IVF has been constrained by manual processes that create barriers to accessibility and inconsistency in performance. Overture's automation addresses real operational challenges that clinics face every day, from embryologist shortages to the need for affordable and predictable outcomes.' About Overture Life Overture Life integrates engineering, reproductive medicine, and regulatory-grade validation to modernize embryology lab procedures, particularly fertility preservation and embryo handling, in ways that lower repeated cycles, increase throughput, and reduce the overall cost of IVF. With R&D in Spain and active U.S. operations, including a CLIA-licensed laboratory for non-invasive embryo selection, Overture unites robotics, analytics, and clinical rigor to deliver tools that clinics and patients can trust. The company's DaVitri platform aims to boost reliability and consistency in IVF, giving women and families worldwide more control over their fertility timelines. Overture's backers include Overwater Ventures, GV (formerly Google Ventures), Khosla Ventures, Octopus Ventures and others committed to advancing the future of fertility.
